       Document 0017
 DOCN  M9640017
 TI    Retroviral vectors for HIV immunotherapy.
 DT    9604
 AU    Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J; Viagene,
       Inc., San Diego, California 92121, USA.
 SO    Ann N Y Acad Sci. 1995 Nov 27;772:105-16. Unique Identifier : AIDSLINE
       MED/96135351
 DE    Animal  AIDS Vaccines/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
       *THERAPEUTIC USE  Cells, Cultured  Clinical Trials, Phase I  Female
       Gene Products, env/GENETICS/*IMMUNOLOGY  Gene Products,
       rev/GENETICS/*IMMUNOLOGY  *Gene Therapy/ADVERSE EFFECTS  *Genetic
       Vectors  Human  HIV Antibodies/*BIOSYNTHESIS  HIV Infections/*THERAPY
       HIV-1/*GENETICS/IMMUNOLOGY  *Immunotherapy, Active/ADVERSE EFFECTS
       Injections, Intramuscular  Macaca mulatta  Male  Mice  Mice, Inbred BALB
       C  Papio  Recombinant Fusion Proteins/GENETICS/*IMMUNOLOGY
       Retroviridae/*GENETICS  Safety  T-Lymphocytes, Cytotoxic/*IMMUNOLOGY
       Vaccines, Synthetic/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
       *THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

